Evidence map›Paper›PMID 39575489›Full record

ArticleMolecular medicine reports2025

Yongting Chen, Linlin Ma, Yuzhong Yan, Xiaoying Wang, Lizhi Cao, Yanfei Li, Ming Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongting Chen *Graduate School, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China.
Linlin Ma *Scientific Research Department, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, P.R. China.
Yuzhong YanScientific Research Department, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, P.R. China.
Xiaoying WangSchool of Life Sciences and Technology, Tongji University, Shanghai 200092, P.R. China.
Lizhi CaoScientific Research Department, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, P.R. China.
Yanfei LiScientific Research Department, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, P.R. China.
Ming LiAdministration Office, East Hospital Affiliated to Tongji University, Shanghai 201318, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX) is a principal chemotherapeutic agent in the domain of oncological intervention. However, its clinical application is constrained due to its severe and irreversible side effects, particularly heart damage. Ferroptosis, characterized by iron accumulation and redox system imbalance, serves a key role in DOX‑induced cardiotoxicity.

Indexed as

DoxorubicinFerroptosisIronMyocytes, CardiacNF-E2-Related Factor 2OphiopogonPhospholipid Hydroperoxide Glutathione PeroxidasePolysaccharidesSignal TransductionAnimalsCardiotoxicityLipid PeroxidationMaleMiceMyocardiumOxidative StressDoxorubicinglutathione peroxidase 4, mouseIronNfe2l2 protein, mouseNF-E2-Related Factor 2Phospholipid Hydroperoxide Glutathione PeroxidasePolysaccharidesReceptors, TransferrinTfrc protein, mousecardiotoxicitydoxorubicinferroptosisNrf2/GPX4 signaling pathwayOphiopogon japonicus polysaccharide

Identifiers

PMID39575489
PMCPMC11605273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.